AAO2016

Small pupils: Maneuvers, medications, mechanical devicesThomas A. Oetting, MD, MS, shared five pearls for operating in eyes with small pupils. In the follow-up discussion, panel members commented on their experiences with newer options for small pupil management.
Managing the growing burden of glaucomaThe number of patients with glaucoma will rise dramatically in the future because of growth in both the size of the aged population and in demographic groups at high-risk for the disease. Ophthalmology, however, is not equipped to handle the increasing demand for services considering workforce projections and current models of care.
Accelerated CXL rivals conventional techniqueResults from 2 years of follow-up in a large, prospective comparative study show that conventional corneal crosslinking (C-CXL) and accelerated CXL (A-CXL) are similarly safe and effective for stabilizing keratoconus progression in eyes with mild-to-moderate disease, said Tulika Chauhan, MD, at AAO 2016.
Improving the prognosis of uveal melanomaAbout one-half of people diagnosed with uveal melanoma ultimately develop metastatic disease. A look at survival rates for patients with uveal melanoma indicate that not much has changed in the past several decades or even for the past 100-plus years. Nevertheless, there is good reason to be optimistic about the future considering the recent developments and ongoing research in this field, said Mary Beth Aronow, MD, at Ocular Oncology and Pathology 2016.
Weighing IOP fluctuation in glaucoma progressionAvailable evidence indicates that long-term IOP fluctuation is an important factor in glaucoma progression, said Joseph Caprioli, MD. Based on this information he encouraged ophthalmologists to consider IOP “modulation” rather than “reduction.”
Looking to long-range keratoprosthesis outcomesFindings from a single-surgeon consecutive series including 97 eyes with up to 12 years of follow-up provide realistic insights for corneal surgeons about long-term outcomes after implantation of the Boston keratoprosthesis type 1 (“Boston KPro”; Massachusetts Eye and Ear Infirmary). The information—which included analyses of visual acuity results, device retention rates, and complications associated with the permanent keratoprosthesis—was presented by Anthony J. Aldave, MD, at Cornea 2016.
Examining NSAID prevention of pseudophakic CMEAdding a topical nonsteroidal anti-inflammatory drug (NSAID) to treatment with a topical corticosteroid significantly reduces the incidence of clinical pseudophakic cystoid macular edema (PCME) in at-risk eyes.
How the cornea contributes to IOL power calculationUnder the best of circumstances—meaning when cataract surgery is performed in an eye with a normal cornea by expert hands and with use of an advanced IOL power calculation formula—the achieved refractive outcome will be more than 0.5 D off target in 1 out of every 11 eyes.
AAO initiatives put focus on patient safetyRecognizing that healthcare errors impact one in every ten patients around the world, the World Health Organization has called patient safety an endemic concern, said Richard L. Abbott, MD, at AAO 2016.
Understanding pros, cons of the latest corneal refractive procedureIn a timely talk at Refractive Surgery Subspecialty Day 2016, Sunil Shah, MD, made a case for why refractive surgeons might want to consider this minimally-invasive corneal refractive procedure.